Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

December 31, 2009

Conditions
Primary DiseaseProstate Cancer
Interventions
DRUG

sorafenib (200 or 400mg bid) and taxotere iv

200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles

Trial Locations (6)

1200

Cliniques Universitaires St Luc, Brussels

1340

St Pierre, Ottignies

5000

Sainte Elisabeth, Namur

5030

Clinique Universiataire de Mont Godinne, Yvoir

6000

Notre Dame et Reine Fabiola, Charleroi

75015

Hôpital Européen Georges Pompidou, Paris

All Listed Sponsors
lead

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

NCT00405210 - Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer | Biotech Hunter | Biotech Hunter